|

Nicorandil as Anti-inflammatory in Rheumatoid Arthritis

RECRUITINGPhase 3Sponsored by Tanta University
Actively Recruiting
PhasePhase 3
SponsorTanta University
Started2024-11-01
Est. completion2027-03
Eligibility
Age18 Years – 70 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07516769

Summary

This study aims to evaluate the possible efficacy and safety of nicorandil as anti-inflammatory in managing patients with active rheumatoid arthritis.

Eligibility

Age: 18 Years – 70 YearsHealthy volunteers accepted
Inclusion Criteria:

* Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) i.e., 28 joints disease activity score (DAS-28) \>2.6.
* Patients receiving the conventional DMARDs

Exclusion Criteria:

* Patients with heart disease (congestive heart failure, arrhythmia and ischemic heart disease), diabetes, active infection, and other illness except rheumatoid arthritis.
* Patients with severe renal and hepatic dysfunction. - Patients receiving biological DMARDs.
* Patients receiving oral prednisolone greater than 15mg/day.
* Patients with hypersensitivity to study medications.
* Patients using antioxidants.
* Pregnant and lactating females.

Conditions2

ArthritisRhumatoid Arthisis

Interventions1

Nicorandil 10 MG Oral Tablet

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.